Omission of Sentinel Lymph Node Biopsy in Breast Cancer: A Real‐World Validation of the Patient Populations of the SOUND and INSEMA Trials

dc.contributor.authorPuiras, Tia
dc.contributor.authorJuhanoja, Eeva
dc.contributor.authorTamminen, Anselm
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organizationfi=sisätautioppi|en=Internal Medicine|
dc.contributor.organizationfi=kirurgia|en=Surgery|
dc.contributor.organization-code2607318
dc.contributor.organization-code1.2.246.10.2458963.20.97295082107
dc.converis.publication-id523650548
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/523650548
dc.date.accessioned2026-06-18T20:10:43Z
dc.description.abstract<p><strong>Background: </strong> Treatment guidelines recommending omission of axillary surgery in breast cancer are largely based on the SOUND and INSEMA trials. However, the extent to which their study populations represent real-world patients remains unclear. We aimed to evaluate the real-world applicability and external validity of these trial populations.</p><p><strong>Materials and methods: </strong> All consecutive patients treated for early breast cancer at a single university hospital between 2010 and 2018 were included. Patients with clinically node-negative disease were identified, and eligibility according to the SOUND and INSEMA inclusion criteria was determined. Clinicopathologic characteristics were compared between trial-eligible real-world patients and published trial populations.</p><p><strong>Results: </strong> A total of 2787 consecutive patients with clinically negative axilla were included; 71% (1982/2787) fulfilled the INSEMA and 52% (1461/2787) the SOUND trial eligibility criteria. Patients eligible in the SOUND trial were largely representative of real-world patients in terms of clinicopathologic characteristics. In contrast, the INSEMA trial appeared more selected, with a higher proportion of biologically favorable tumors. Both trials predominantly included patients with small (< 2 cm) luminal breast cancers. Patients with larger tumors and more aggressive subtypes were underrepresented.</p><p><strong>Conclusion: </strong> The SOUND and INSEMA eligibility criteria are broadly applicable to real-world patients with small luminal breast cancers. However, differences between trial populations and real-world patients highlight the need for careful consideration when applying SLNB omission beyond these lower-risk subgroups.</p><p><strong>Keywords: </strong> axillary lymph node dissection; breast cancer; de‐escalation; sentinel lymph node biopsy; surgery.</p>
dc.identifier.eissn1096-9098
dc.identifier.jour-issn0022-4790
dc.identifier.urihttps://www.utupub.fi/handle/11111/62159
dc.identifier.urlhttps://doi.org/10.1002/jso.70256
dc.identifier.urnURN:NBN:fi-fe2026052958279
dc.language.isoen
dc.okm.affiliatedauthorJuhanoja, Eeva
dc.okm.affiliatedauthorTamminen, Anselm
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3126 Surgery, anesthesiology, intensive care, radiologyen_GB
dc.okm.discipline3126 Kirurgia, anestesiologia, tehohoito, radiologiafi_FI
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherWiley
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.articlenumberjso.70256
dc.relation.doi10.1002/jso.70256
dc.relation.ispartofjournalJournal of Surgical Oncology
dc.titleOmission of Sentinel Lymph Node Biopsy in Breast Cancer: A Real‐World Validation of the Patient Populations of the SOUND and INSEMA Trials
dc.year.issued2026

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
Journal of Surgical Oncology - 2026 - Puiras - Omission of Sentinel Lymph Node Biopsy in Breast Cancer A Real‐World.pdf
Size:
646.88 KB
Format:
Adobe Portable Document Format